In November, Diaverum had the privilege of hosting the Swecare Board at our Global HQ as part of their Annual Board Visit, which in 2024 took place in Malmö and Lund.
Led by Chairman Agneta Karlsson and CEO Maria Helling, Swecare is a non-profit organisation whose aim is to bring together the very best of the country’s healthcare academia, public and private sectors.
Diaverum’s cohort was led by Global Director of Patient Experience & Stakeholder Management, Michaela Blomstrand, who was elected to the Board of Swecare in 2024. Michaela’s central role in the organisation, places Diaverum at the helm of a group of more than 100 organisations that aim to promote insights & experience gained through Sweden’s healthcare system, widely regarded as one of the most advanced globally.
Monday, 11 November
The Swecare Board Meeting got to an insightful start, with a visit to the recently launched extension of Malmö’s Skåne University Hospital. Valued at over 12bn SEK (or €1.9bn), it involves a large-scale redevelopment of the facility, aimed at creating a modern, sustainable, and innovative university hospital.
Following the visit, the Board arrived at Diaverum HQ, where senior executives, including CEO Dimitris Moulavasilis, and Country Managers, José María Ordóñez and Dimitar Klisarovski, from Spain and North Macedonia, respectively, had the opportunity to share its success story as a Sweden-born, multinational organisation with over 30 years of growth, renowned clinical outcomes, and a strong international presence, establishing ourselves as a leader in renal care globally. Additionally, ESG Global Manager, Stephanie de Sury, outlined Diaverum’s sustainability approach, while Regional Operations Director, Sergio Rodriguez, discussed potential avenues for expanding Diaverum's network of clinics in Sweden.
To close the day, Diaverum also had the pleasure of hosting Swecare’s Life Science Mingle, bringing together over 50 top industry leaders to network and explore future collaboration opportunities within the life sciences sector.
Tuesday, 12 November
The second day included a visit to MAX IV, the world’s most energy-efficient synchrotron, offering advanced X-ray spectroscopy, scattering, and imaging techniques that contribute to cutting-edge research across diverse scientific fields. The Board also visited Skånecare, another Swecare member. The trip concluded with a board meeting in Lund, where the Board reviewed Swecare’s strategic priorities and focus areas for 2025, a year set to bring exciting developments in Swedish healthcare.
Reflecting on the visit, Dimitris Moulavasilis, CEO of Diaverum, shared his enthusiasm: "We are excited to continue strengthening our collaboration with Swecare. Together, we can leverage Swedish healthcare’s high standards and expertise to positively impact renal patients and healthcare systems around the world. Diaverum’s life-enhancing renal care services are the result of over three decades of innovation, and we look forward to expanding this legacy globally in partnership with Swecare".
For her part, Michaela added: "It was a true privilege to lead Diaverum’s cohort during this insightful visit, where we had the opportunity to showcase how our Swedish heritage and global presence are helping to redefine renal care worldwide. Being part of the Swecare Board, alongside over 100 of our healthcare peers, allows us to play a vital role in promoting the valuable insights and innovative practices of Sweden’s healthcare system, which continues to set a global benchmark".